The Effects of Group Motivational Interviewing Compliance Therapy on Drug Attitude, Medicine Application Self-efficacy and Medicine Application in Psychiatric Patients

Dawoon Lee; Sungjae Kim

doi:10.12934/jkpmhn.2017.26.4.391

Journal List > J Korean Acad Psychiatr Ment Health Nurs > v.26(4) > 1058138

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Lee and Kim: The Effects of Group Motivational Interviewing Compliance Therapy on Drug Attitude, Medicine Application Self-efficacy and Medicine Application in Psychiatric Patients

Original Article

J Korean Acad Psychiatr Ment Health Nurs 2017;26(4):391-401.

Published online: 17 December 2017

DOI: https://doi.org/10.12934/jkpmhn.2017.26.4.391

The Effects of Group Motivational Interviewing Compliance Therapy on Drug Attitude, Medicine Application Self-efficacy and Medicine Application in Psychiatric Patients

Dawoon Lee¹, Sungjae Kim²

¹Department of Nursing, Seoul National University Hospital, Seoul, Korea

²College of Nursing · The Research Institute of Nursing Science, Seoul National University, Seoul, Korea

Corresponding author: Kim, Sungjae College of Nursing, Seoul National University, 103 Daehak-ro, Jongno-gu, Seoul 03080, Korea. Tel: +82-2-740-8814, Fax: +82-2-765-4103, E-mail: sungjae@snu.ac.kr

Received 26 September 201711 November 2017 Accepted 6 December 2017

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Purpose

This study aims to verify the effects of the Group Motivational Interviewing Compliance Therapy on drug attitude, medicine application self-efficacy and medicine application in psychiatric patients.

Methods

This was a quasi-experimental study with a non-equivalent control group pre-posttest design. Participants were 43 patients (22 in experimental group and 21 in control group) who were registered at neuro-psychiatric day care center in one university hospital, S city. The experimental group received the Group Motivational Interviewing Compliance Therapy for 6 sessions over 6 weeks. Data were collected between November, 2014 and September, 2016. Comparison of the pre-post results was performed by paired t-test and between-group effect was analyzed by ANCOVA with the SPSS/WIN 23.0 program.

Results

The experimental group had a significant increase in drug attitude compared to the control group. However, there was no significant difference in medicine application self-efficacy and medicine application between the two groups.

Conclusion

The Group Motivational Interviewing Compliance Therapy is suggested as a promising program that helps psychiatric patients improve drug attitude. Further studies are needed to confirm the effects of the Group Motivational Interviewing Compliance Therapy.

Keywords: Motivational interviewing, Mesh, Drug attitude, Self-efficacy, Medication adherence

REFERENCES

1. You JH, Woo YS, Hahn C, Choi JW, Ko HJ. Predicting factors associated with drug compliance in psychiatric outpatients of a university hospital. The Korean Journal of Psychopharmacology. 2010; 21:29–34.

2. Kim JE, Moon JJ, Kim MH, Kim WJ, Park MK, Song TH, et al. Effects of psychoeducation program on insight and treatment attitudes in patients with schizophrenia, schizophreniform disorder, and schizoaffective disorder. The Korean Journal of Psychopharmacology. 2010; 21:87–94.

3. Julius RJ, Novitsky MA Jr, Dubin WR. Medication adherence: a review of the literature and implications for clinical practice. Journal of psychiatric practice. 2009; 15(1):34–44. https://doi.org/10.1097/01.pra.0000344917.43780.77.

4. Kampman O, Lehtinen K. Compliance in psychoses. Acta psychiatrica Scandinavica. 1999; 100(3):167–175. https://doi.org/10.1111/j.1600-0447.1999.tb10842.x.

5. Lee PS. A study on nurses' and patients' perceptions of psychotropic medication. Journal of Nurses Academic Society. 1994; 24(1):47–57.

6. Kemp R, Kirov G, Everitt B, Hayward P, David A. Randomised controlled trial of compliance therapy. 18-month followup. The British Journal of Psychiatry. 1998; 172(5):413–419. https://doi.org/10.1192/bjp.172.5.413.

7. Mutsatsa SH, Joyce EM, Hutton SB, Webb E, Gibbins H, Paul S, et al. Clinical correlates of early medication adherence: West London first episode schizophrenia study. Acta Psychiatrica Scandinavica. 2003; 108(6):439–446. https://doi.org/10.1046/j.0001-690X.2003.00193.x.

8. Beebe LH, Smith K, Phillips C. Descriptions and correlates of medication adherence, attitudes, and self-efficacy in outpatients with schizophrenia spectrum disorders (SSDs). Archives of Psychiatric Nursing. 2016; 30(3):400–405. https://doi.org/10.1016/j.apnu.2016.01.010.

9. Marland GR. Atypical neuroleptics: autonomy and compliance? Journal of Advanced Nursing. 1999; 29(3):615–622. https://doi.org/10.1046/j.1365-2648.1999.00930.x.

10. Barkhof E, Meijer CJ, de Sonneville LM, Linszen DH, de Haan L. Interventions to improve adherence to antipsychotic medication in patients with schizophrenia–a review of the past decade. European psychiatry. 2012; 27(1):9–18. https://doi.org/10.1016/j.eurpsy.2011.02.005.

11. Gray R, Wykes T, Gournay K. From compliance to concordance: a review of the literature on interventions to enhance compliance with antipsychotic medication. Journal of Psychiatric and Mental Health Nursing. 2002; 9(3):277–284.

12. Lee J, Bae J, Im S. Review of nursing research on psychotropic drugs in Korea. Journal of Korean Public Health Nursing. 2013; 27(2):338–356. https://doi.org/10.5932/JKPHN2013.27.2.338.

13. Miller WR, Rollnick S. Motivational Interviewing: Preparing People for Change. 2nd ed.New York: Guilford Press;2002. p. 425.

14. Kemp R, Hayward P, Applewhaite G, Everitt B, David A. Compliance therapy in psychotic patients: randomised controlled trial. British Medical Journal. 1996; 312(7027):345–349. https://doi.org/10.1136/bmj.312.7027.345.

15. Omranifard V, Karahmadi M, Jannesary Z, Maracy M. Efficacy of modified compliance therapy for schizophrenia patients. Journal of Research in Medical Sciences. 2012; Special Issue. (2):258–263. https://doi.org/10.1016/S0924-9338(13)76898-6.

16. Tay SEC. Compliance therapy: an intervention to improve inpatients' attitudes toward treatment. Journal of Psychosocial Nursing and Mental Health Services. 2007; 45(6):29–37.

17. Teesson M, Sannibale C, Reid S, Proudfoot H, Gournay K, Haber P. Manual for compliance therapy in alcohol pharmacotherapy. Technical Report. Sydney: National Drug and Alcohol Research Centre;2003. Report No.157.

18. Joung J, Kim S. Effects of a relapse prevention program on insight, empowerment and treatment adherence in patients with schizophrenia. Journal of Korean Academy of Nursing. 2017; 47(2):188–198. https://doi.org/10.4040/jkan.2017.47.2.188.

19. Yoon BH, Bahk WM, Lee KU, Hong CH, Ahn JK, Kim MK. Psychometric properties of Korean Version of Drug Attitude Inventory (KDAI-10). Korean Journal of Psychopharmacology. 2005; 16(6):480–487.

20. Lee HJ. Factors affecting medication compliance of hypertensive patients [master's thesis]. [Seoul]: Dankook University;2002. p. 79.

21. Hwang MS. Effects of the medication education on medication knowledge and medication compliance with schizophrenia [master's thesis]. [Seoul]: Yonsei University;1998. p. 51.

22. Shin GS. Effect of home visit education on the drug compliance for chronic schizophrenics in house and the caregiver's role [master's thesis]. [Chuncheon]: Kangwon National University;2001. p. 100.

23. Kim SY. A review on the statistical method for quasi-experimental data of nonequivalence control group design in nursing research. Journal of the Korean Data Analysis Society. 2005; 7(1):113–124.

24. Barkhof E, Meijer CJ, de Sonneville LM, Linszen DH, de Haan L. The effect of motivational interviewing on medication adherence and hospitalization rates in nonadherent patients with multi-episode schizophrenia. Schizophrenia Bulletin. 2013; 39(6):1242–1251. https://doi.org/10.1093/schbul/sbt138.

25. Wagner CC, Ingersoll KS. Motivational Interviewing in Groups. New York: Guilford Press;2012. p. 416.

26. Cha BK, Chang HK, Sohn JN. A metaanalysis of the effects of a self-efficacy promoting program. Journal of Korean Academy of Nursing. 2004; 34(6):934–944.

27. Song HR. Relationship among attitude toward drug, medication adherence, and internalized stigma of psychiatric outpatients [master's thesis]. [Seoul]: Kyung Hee University;2012. p. 74.

28. Seo M, Kim HR. Effectiveness of an 'integrated medication adherence enhancement program for persons with schizophrenia' by using online education contents. The Korean Journal of Psychopharmacology. 2009; 20(1):22–31.

29. Kwon JS, Shin SW, Cheong YM, Park KH. Medication compliance in psychiatric outpatients of a university hospital. Journal of Korean Neuropsychiatry Association. 1997; 36(3):523–529.

Table 1.

Sessions & Contents of the Group Motivational Interviewing Compliance Therapy

Session	Contents
1	Pretest Introduction of group motivational interviewing compliance therapy Eliciting the patient's stance towards treatments - Review of history
2	Review of history and share - Linking treatment completion with effecting changes - Formulating model of beliefs about problems and treatments Needs for treatment
3	Explore ambivalence towards treatment - Asking common causes for resistance to treatment - Correcting any misconceptions and providing feedback about side effects reported by patients
4	Exploring good and bad aspect of medication Focusing on the effect of the medication - Indirect medication benefit Life satisfaction: looking forward
5	Highlighting the need for treatment-maintenance Encourage self-efficacy - Movie 'Beautiful mind'
6	Emphasize value of staying well to achieve goals Predict consequences of not taking medication Relapse prevention Explain other aids to help adherence Establish plans to take medication
	Posttest (1 week later after 6 session)

Table 2.

Homogeneity Test of Sociodemographic Characteristics, Diagnosis, Age of First Hospitalization, Frequency of Hospitalization and Medication Non-adherence Experience of Participants (N=43)

Characteristics	Categories	Exp. (n=22)	Cont. (n=21)	Total (N=43)	χ² or t	p
Characteristics	Categories	n (%) or M±SD	n (%) or M±SD	n (%) or M±SD	χ² or t	p
Gender	Male	16 (72.7)	12 (57.1)	28 (65.1)	1.15	.284
Gender	Female	6 (27.3)	9 (42.9)	15 (34.9)
Age (year)		26.91±7.96	29.71±7.62	28.28±7.83	1.18	.245
Marital status	Married	1 (4.5)	0 (0.0)	1 (2.3)		＞.999
	Never married	21 (95.5)	20 (95.2)	41 (95.3)
	Divorce or separation of death	0 (0.0)	1 (4.8)	1 (2.3)
Education	≤High school	9 (40.9)	9 (42.9)	18 (41.9)		＞.999
	College	5 (22.7)	6 (28.6)	11 (25.6)
	≥College	6 (27.3)	5 (34.8)	11 (25.6)
	Other	2 (9.1)	1 (4.8)	3 (7.0)
Religion	Buddhism	1 (4.5)	1 (4.8)	2 (4.7)		.831
	Catholicism	2 (9.1)	2 (9.5)	4 (9.3)
	Protestantism	10 (45.5)	6 (28.6)	16 (37.2)
	Other	2 (9.1)	2 (9.5)	4 (9.3)
	None	7 (31.8)	10 (47.6)	17 (39.5)
Monthly income (10,000 won)	＜100	4 (18.2)	0 (0.0)	4 (9.3)		.133
	100~200	2 (9.1)	7 (33.3)	9 (20.9)
	200~300	4 (18.2)	4 (19.0)	8 (18.6)
	300~400	4 (18.2)	3 (14.3)	7 (16.3)
	400~500	3 (13.6)	5 (23.8)	8 (18.6)
	＞500	5 (22.7)	2 (9.5)	7 (16.3)
Diagnosis	Schizophrenia^†	15 (68.2)	14 (66.7)	29 (67.4)		＞.999
	Bipolar disorder^‡	3 (13.6)	2 (9.5)	5 (11.6)
	Depressive disorder	2 (9.1)	2 (9.5)	4 (9.3)
	Obsessive compulsive disorder	1 (4.5)	2 (9.5)	3 (7.0)
	Others^§	1 (4.5)	1 (4.8)	2 (4.7)
Age of first hospitalization		22.82±7.01	24.38±8.92	23.58±7.94	-0.64	.526
Frequency of hospitalization		3.45±2.24	3.33±2.11	3.40±2.15	0.18	.856
Medication non-adherence experience	Yes	12 (54.5)	9 (42.9)	21 (48.8)	0.59	.443
	No	10 (45.5)	12 (57.1)	22 (51.2)

Exp.=Experimental group; Cont.=Control group;

^† Schizophrenia spectrum and other psychotic disorder include schizophrenia, schizoaffective disorder and psychotic disorder;

^‡ Bipolar disorder include bipolar Ⅰ&Ⅱ disorder;

^§ Posttraumatic stress disorder, social phobia.

Table 3.

Homogeneity Test of Values of Dependent Variables at Pretest (N=43)

Variables	Exp. (n=22)	Cont. (n=21)	Total (N=43)	t	p
Variables	n (%) or M±SD	n (%) or M±SD	n (%) or M±SD	t	p
DAI	3.55±3.56	2.86±4.54	3.21±4.05	0.55	.584
MASe	31.55±3.85	32.48±4.42	32.00±4.12	-0.73	.465
MA	29.64±3.03	29.33±3.45	29.49±3.21	0.31	.761

Exp.=Experimental group; Cont.=Control group; DAI=Drug attitude inventory; MASe=Medicine application self-efficacy; MA=Medicine application.

Table 4.

Comparison of the Differences of the Drug Attitude Inventory, Medicine Application Self-efficacy, Medicine Application between Groups (N=43)

Variables	Groups	Pre	Post	t	p	Differences	F^†	p
Variables	Groups	M±SD	M±SD	t	p	M±SD	F^†	p
DAI	Exp. (n=22)	3.55±3.56	5.82±2.82	3.19	.004	2.27±3.34	8.54	.006
	Cont. (n=21)	2.86±4.54	3.05±3.83	0.25	.803	0.19±3.46
MASe	Exp. (n=22)	31.55±3.85	33.86±3.85	3.71	.001	2.32±2.93	2.14	.152
	Cont. (n=21)	32.48±4.42	32.90±4.53	0.45	.661	0.43±4.41
MA	Exp. (n=22)	29.64±3.03	30.82±2.58	2.05	.053	1.18±2.70	0.30	.589
	Cont. (n=21)	29.33±3.45	30.29±3.02	1.67	.111	0.95±2.62

Exp.=Experimental group; Cont.=Control group; DAI=Drug attitude inventory; MASe=Medicine application self-efficacy; MA=Medicine application;

^† ANCOVA conducted with covariate of pretest value.

TOOLS

Similar articles